Organization · Venture Capital
FundPlus
FundPlus is a Belgian private foundation focused on long-term equity investments in innovative life sciences companies, primarily in therapeutics, diagnostics, and medical devices. It aims to create sustainable shareholder value and contribute to the life sciences sector.
Overview
What FundPlus does
What FundPlus is
FundPlus is a Belgian private foundation focused on long-term equity investments in innovative life sciences companies, primarily in therapeutics, diagnostics, and medical devices. It aims to create sustainable shareholder value and contribute to the life sciences sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2015
- Approximate age
- About 11 years
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find FundPlus elsewhere
Open the official website or a supported primary organization account.
Capability profile
FundPlus as a funder
Investment thesis
Fund+ focuses on long-term equity investments in innovative life sciences companies, primarily in therapeutics, diagnostics, and medical devices, aiming to create sustainable shareholder value and societal impact.
Focus narrative
Fund+ invests in innovative life sciences companies that are primarily active in therapeutics, diagnostics, and medical devices. The fund targets companies seeking Series A or B financing that have already achieved proof of concept. The intended investment size per company ranges from €5 million to €15 million, distributed over various milestones. Fund+ aims to be a significant minority shareholder (more than 10%) and plays a constructive role as a board member in its portfolio companies, focusing on investments in Europe, particularly Belgium.
Value beyond capital
Fund+ adds value to its portfolio companies by taking significant minority stakes and actively participating as board members, providing strategic guidance and support to help them achieve their milestones and grow sustainably.
Terms and economics
- Typical check
- $5,000,000–$15,000,000
Focus and fit
- Stages
- Series A · Series B
- Regions
- Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 7
Portfolio context
Notable portfolio companies include: Minoryx: A clinical-stage biotech company developing therapies for orphan CNS diseases. AstriVax Therapeutics: A spin-off from KU Leuven, focused on developing a Plug & Play vaccine platform for infectious diseases. Coave Therapeutics: Developing gene-therapy treatments for rare inherited retinal diseases. Immunic Therapeutics: Focuses on selective oral immunology therapies for chronic inflammatory and autoimmune diseases. eTheRNA Immunotherapies: Applying mRNA-based immunotherapies for cancer treatment. Novadip Biosciences: Developing solutions for critical tissue reconstruction. Cellaïon: Focused on advanced clinical development for liver failure treatments.
Common questions
What to know about FundPlus
Upseed classifies FundPlus under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.